GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Renalytix PLC (LSE:RENX) » Definitions » Loans Receivable

Renalytix (LSE:RENX) Loans Receivable : £0.00 Mil (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Renalytix Loans Receivable?

Renalytix's Loans Receivable for the quarter that ended in Mar. 2024 was £0.00 Mil.


Renalytix Loans Receivable Historical Data

The historical data trend for Renalytix's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renalytix Loans Receivable Chart

Renalytix Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Loans Receivable
Get a 7-Day Free Trial - - - - -

Renalytix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Renalytix Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Renalytix Loans Receivable Related Terms

Thank you for viewing the detailed overview of Renalytix's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Renalytix (LSE:RENX) Business Description

Traded in Other Exchanges
Address
5-7 Cranwood Street, Finsgate, London, GBR, EC1V 9EE
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Renalytix (LSE:RENX) Headlines

From GuruFocus

Paul Singer Buys Reed Elesvier

By matsandalex matsandalex 12-14-2012

Investing in Information

By Vanina Egea Vanina Egea 03-06-2014

Causeway International's Top Five Holdings

By Monica Wolfe Monica Wolfe 08-29-2013